A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer.

被引：0
|
作者：
Chua, Melvin
Murgic, Jure
Hosni, Ali
Salcedo, Adriana
Kamel-Reid, Suzanne
Berlin, Alejandro
Pintile, Melania
Fraser, Michael
Van Der Kwast, Theodorus
Boutros, Paul Christopher
Bristow, Robert G.
机构：
[1] Natl Canc Ctr Singapore, Singapore, Singapore
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Ontario Inst Canc Res, Toronto, ON, Canada
[4] Univ Hlth Network, Toronto, ON, Canada
[5] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON, Canada
[7] Manchester Canc Res Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.68
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
68
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Robustness of the Phoenix Biochemical Failure Definition 10 Years after Completing Dose Escalated Radiotherapy in a Cohort of Intermediate Risk Prostate Cancer Patients
    Aljawi, G. A.
    Busca, I.
    MacRae, R. M.
    Eapen, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E261 - E261
  • [42] ROBUSTNESS OF THE PHOENIX BIOCHEMICAL FAILURE DEFINITION 10 YEARS AFTER COMPLETING DOSE ESCALATED RADIOTHERAPY IN A COHORT OF INTERMEDIATE RISK PROSTATE CANCER PATIENTS
    Aljawi, Ghufran
    Busca, Ionut
    MacRae, Robert
    Eapon, Libni
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S48 - S49
  • [43] External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer
    Lee, David I.
    Shahait, Mohammed
    Dalela, Deepansh
    Keeley, Jacob
    Lal, Priti
    Vapiwala, Neha
    Abdollah, Firas
    WORLD JOURNAL OF UROLOGY, 2021, 39 (09) : 3217 - 3222
  • [44] External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer
    David I. Lee
    Mohammed Shahait
    Deepansh Dalela
    Jacob Keeley
    Priti Lal
    Neha Vapiwala
    Firas Abdollah
    World Journal of Urology, 2021, 39 : 3217 - 3222
  • [45] Re: A Biopsy-Based 17-Gene Genomic Prostate Score Predicts Recurrence after Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low-and Intermediate-Risk Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2015, 193 (05): : 1541 - 1541
  • [46] Prognostic value of initial PSA, PSA Nadir and time to Nadir PSA for biochemical failure in patients with intermediate-risk prostate cancer treated with radiation therapy without androgen deprivation
    Patel, N.
    Souhami, L.
    Mansure, J. J.
    Faria, S.
    Duclos, M.
    Shenouda, G.
    David, M.
    Cury, F. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S710 - S710
  • [47] Impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or without androgen deprivation therapy for unfavorable-risk prostate cancer.
    Patel, Sagar Anil
    Chen, Ming-Hui
    Loffredo, Marian
    Renshaw, Andrew A.
    Kantoff, Philip W.
    D'Amico, Anthony Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [48] Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy With or Without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer
    Freytag, Svend O.
    Stricker, Hans
    Lu, Mei
    Elshaikh, Mohamed
    Aref, Ibrahim
    Pradhan, Deepak
    Levin, Kenneth
    Kim, Jae Ho
    Peabody, James
    Siddiqui, Farzan
    Barton, Kenneth
    Pegg, Jan
    Zhang, Yingshu
    Cheng, Jingfang
    Oja-Tebbe, Nancy
    Bourgeois, Renee
    Gupta, Nilesh
    Lane, Zhaoli
    Rodriguez, Ron
    DeWeese, Theodore
    Movsas, Benjamin
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (02): : 268 - 276
  • [49] Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer
    Ong, Wee Loon
    Foroudi, Farshad
    Evans, Sue
    Millar, Jeremy
    BJU INTERNATIONAL, 2017, 120 : 35 - 42
  • [50] Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial
    Morris, W. James
    Pickles, Tom
    Keyes, Mira
    BRACHYTHERAPY, 2018, 17 (06) : 837 - 844
12345